These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 535126)

  • 1. Mathematical modeling -- guide to high-dose methotrexate infusion therapy.
    Reich SD
    Cancer Chemother Pharmacol; 1979; 3(1):25-31. PubMed ID: 535126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
    Goh TS; Wong KY; Lampkin B; O'Leary J; Gnarra D
    Cancer Chemother Pharmacol; 1979; 3(3):177-80. PubMed ID: 316745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.
    Mitchell MS; Wawro NW; DeConti RC; Kaplan SR; Papac R; Bertino JR
    Cancer Res; 1968 Jun; 28(6):1088-94. PubMed ID: 4298056
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
    Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
    N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
    Luyckx M; Cazin JL; Brunet C; Gosselin P; Demaille MC
    Eur J Clin Pharmacol; 1985; 28(4):457-62. PubMed ID: 3839754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
    Thomson AH; Daly M; Knepil J; Harden P; Symonds P
    Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of linear and tapered intravenous infusion of methotrexate in oncochemotherapy. A theoretical approach.
    Termond EF; Zonnenberg B; Winograd B; Oosterbaan MJ; Van der Kleijn E; Vree TB
    Pharm Weekbl Sci; 1985 Aug; 7(4):158-62. PubMed ID: 4047914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic approaches to advanced carcinoma of the larynx.
    Bertino JR
    Can J Otolaryngol; 1975; 4(3):492-4. PubMed ID: 52396
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
    Lokich JJ; Curt G
    Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of epidermoid carcinoma of the oro-pharyngo-laryngeal area with combination of methotrexate and bleomycin].
    Broquet MA; Jacot-Descombe E; Montandon A; Alberto P
    Schweiz Med Wochenschr; 1974 Jan; 104(1):18-22. PubMed ID: 4128917
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
    Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
    Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.
    Lokiec F; Poirier O; Gisselbrecht C; Marty M; Boiron M; Najean Y
    Cancer Chemother Pharmacol; 1982; 9(3):165-8. PubMed ID: 7160052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate and radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, oropharynx, supraglottic larynx, and hypopharynx. (Preliminary report of a controlled clinical trial of the Radiation Therapy Oncology Group).
    Kramer S
    Can J Otolaryngol; 1975; 4(2):213-8. PubMed ID: 1139418
    [No Abstract]   [Full Text] [Related]  

  • 16. Methotrexate in combination with radiotherapy in the treatment of squamous carcinomas of the head and neck.
    Klimo J; Danko T
    Neoplasma; 1974; 21(4):451-4. PubMed ID: 4431542
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of pleural effusion on high-dose methotrexate kinetics.
    Evans WE; Pratt CB
    Clin Pharmacol Ther; 1978 Jan; 23(1):68-72. PubMed ID: 618710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate therapy for squamous cell carcinomas of the head and neck. Intermittent intravenous dose program.
    Lane M; Moore JE; Levin H; Smith FE
    JAMA; 1968 May; 204(7):561-4. PubMed ID: 5694477
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer.
    Taylor SG; McGuire WP; Hauck WW; Showel JL; Lad TE
    J Clin Oncol; 1984 Sep; 2(9):1006-11. PubMed ID: 6332178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.